ArticleLupus science & medicine2026
Diagnostic value of cerebrospinal fluid antisuprabasin antibody in neuropsychiatric systemic lupus erythematosus.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiagnostic attribution of neuropsychiatric symptoms in SLE (NPSLE) remains challenging. This study evaluated whether cerebrospinal fluid (CSF) antisuprabasin (SBSN) antibody can serve as a diagnostic biomarker for NPSLE.
methodsIn this single-centre, prospective cohort study, patients with SLE presenting with new-onset neuropsychiatric or neurological symptoms were screened between January 2022 and October 2025. Final diagnoses were adjudicated by an independent committee blinded to CSF anti-SBSN antibody results. Patients were classified as NPSLE, SLE with central nervous system infection (SLE-CNSI) or SLE without NPSLE or CNS infection (SLE-Other). CSF anti-SBSN antibody levels were measured by ELISA. Diagnostic performance was assessed for identifying NPSLE against a combined non-NPSLE comparator group comprising SLE-CNSI and SLE-Other.
resultsAmong 190 screened patients, 148 were included in the final analysis, including 48 with NPSLE, 59 with SLE-CNSI and 41 with SLE-Other. CSF anti-SBSN antibody levels showed a stepwise increase across groups, with median concentrations of 47.60 ng/mL in SLE-Other, 72.82 ng/mL in SLE-CNSI and 88.94 ng/mL in NPSLE; all pairwise comparisons were significant (all p<0.001). For identifying NPSLE versus non-NPSLE comparators, CSF anti-SBSN antibody achieved an area under the receiver operating characteristic curve (AUROC) of 0.830, with a sensitivity of 0.812 and specificity of 0.740 at the optimal cut-off of 76.36 ng/mL. CSF anti-SBSN antibody had a higher AUROC than CSF white blood cell count (0.830 vs 0.743; p=0.041) and serum antiribosomal P antibody (0.830 vs 0.665; p=0.003). The three-marker model further increased the AUROC to 0.892 and significantly outperformed CSF anti-SBSN antibody alone (p=0.009).
conclusionCSF anti-SBSN antibody was significantly elevated in NPSLE and demonstrated good diagnostic performance for identifying NPSLE among patients with SLE presenting with neuropsychiatric symptoms. These findings support CSF anti-SBSN as a promising candidate diagnostic biomarker for NPSLE, particularly when combined with conventional CSF inflammatory and serological markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.